Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

NCT01545050 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT01545050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01545050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Lead sponsor
CSL Behring
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2012
Completion date
December 31, 2013
Enrollment
72 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease